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Abstract
Human serum albumin (HSA), the most abundant protein in human plasma, could be considered as a prototypic monomeric
allosteric protein, since the ligand-dependent conformational adaptability of HSA spreads beyond the immediate proximity
of the binding site(s). As a matter of fact, HSA is a major transport protein in the bloodstream and the regulation of the
functional allosteric interrelationships between the different binding sites represents a fundamental information for the
knowledge of its transport function. Here, kinetics and thermodynamics of the allosteric modulation: (i) of carbon monoxide
(CO) binding to ferrous human serum heme-albumin (HSA-heme-Fe(II)) by warfarin (WF), and (ii) of WF binding to HSA-
heme-Fe(II) by CO are reported. All data were obtained at pH 7.0 and 25uC. Kinetics of CO and WF binding to the FA1 and
FA7 sites of HSA-heme-Fe(II), respectively, follows a multi-exponential behavior (with the same relative percentage for the
two ligands). This can be accounted for by the existence of multiple conformations and/or heme-protein axial coordination
forms of HSA-heme-Fe(II). The HSA-heme-Fe(II) populations have been characterized by resonance Raman spectroscopy,
indicating the coexistence of different species characterized by four-, five- and six-coordination of the heme-Fe atom. As a
whole, these results suggest that: (i) upon CO binding a conformational change of HSA-heme-Fe(II) takes place (likely
reflecting the displacement of an endogenous ligand by CO), and (ii) CO and/or WF binding brings about a ligand-
dependent variation of the HSA-heme-Fe(II) population distribution of the various coordinating species. The detailed
thermodynamic and kinetic analysis here reported allows a quantitative description of the mutual allosteric effect of CO and
WF binding to HSA-heme-Fe(II).
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Introduction
Human serum albumin (HSA), the most abundant protein in
human plasma (with a bloodstream concentration of about
0.7 mM), binds a wide variety of endogenous ligands including
non-esterified fatty acids, bilirubin, hemin and hormones. HSA
also binds exogenous ligands, such as drugs, undertaking their
distribution and delivery, thus representing an important deter-
minant of pharmacokinetics. Physiological or pathological condi-
tions that induce variations in the plasma level of HSA as well as
genetic polymorphisms of HSA could alter exogenous and
endogenous ligand binding, compromising their transport and
metabolism [1–3].
HSA is a monomer composed by 585 amino acid residues
ordered in three homologous a-helical domains (I–III); each
domain is divided into the A and B subdomains connected by
random coils. Terminal regions of sequential domains contribute
to the formation of interdomain a-helices linking subdomains IB to
IIA, and IIB to IIIA (Fig. 1A) [1,3,4–18].
The structural organization of HSA provides a variety of
functionally linked binding sites. In particular, the heme binds with
high affinity (Kd , 161028 M) [19,20] within a narrow oblate
hydrophobic cavity in the HSA subdomain IB [12,14,21], which is
called fatty acid binding site 1 (FA1; see Fig. 1A) and represents the
‘‘heme binding cleft’’. This cavity is limited by Tyr138 and Tyr161
residues that provide p-p stacking interactions with the porphyrin
and supply a donor oxygen (from Tyr161) to the heme-Fe(III)-
atom for the formation of human serum heme-albumin (HSA-
heme) [3,12,14,19,21–23]. Further, two main drug-binding
pockets are Sudlow’s site I (located in subdomain IIA and
corresponding to the FA3-FA4 cleft) and Sudlow’s site II (located
in subdomain IIIA and corresponding to the FA7 site). Warfarin
(WF) and ibuprofen (IBU) are considered as the stereotype ligands
for the FA7 and the FA3-FA4 cleft, respectively. However,
ibuprofen binds also to the FA2 and FA6 secondary sites,
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Figure 1. HSA Structure. (A) Ribbon representation of HSA-heme-Fe(III) The six subdomains of HSA are coloured as follows: subdomain IA, green;
subdomain IB, cyan; subdomain IIA, red; subdomain IIB, orange; subdomain IIIA, blue; and subdomain IIIB, purple. (B) Enlarged view of allosteric FA1
and FA7 heme-Fe(III) sites. Heme-Fe(III) (in red) and WF (in black) are rendered as balls and sticks. Atomic coordinates were taken from PDB entries
1O9X [14] and 2BXD [29]. The structural model was drawn with the UCSF Chimera package.
doi:10.1371/journal.pone.0058842.g001
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moreover FA2 has been postulated to be the secondary site of WF
[1,3,6,10,11,24–29]. Therefore, the occurrence of multiple bind-
ing pockets allows an allosteric behaviour of HSA due to the fact
that the ligand occupancy of one (or more) sites(s) brings about an
alteration of the functional properties of the other ones. Thus, the
heme-binding cleft (i.e., FA1) and Sudlow’s site I (i.e., FA7) are
allosterically coupled (Fig. 1B), since the heme-Fe(III) affinity for
HSA decreases by about one order of magnitude upon WF
binding; accordingly, heme-Fe(III) binding to HSA decreases the
affinity of ligands (e.g., drugs) for Sudlow’s site I by the same extent
[3,17,19–21,30–35].
Ferrous HSA-heme (HSA-heme-Fe(II)) binds nitrogen monox-
ide (NO) and carbon monoxide (CO) and exhibits a weak catalase
and peroxidase activity, involving the heme-Fe complex in the
maintenance of antioxidative homeostasis in the extracellular
fluids [3,8,13,26,36–44]. Remarkably, HSA-heme-Fe(II) reactivity
has been reported to be modulated allosterically by drugs, indeed
abacavir facilitates peroxynitrite-mediated oxidation of ferrous
nitrosylated HSA (HSA-heme-Fe(II)-NO), in the absence and
presence of CO2 [42]. Moreover, abacavir, IBU and WF facilitate
NO dissociation from HSA-heme-Fe(II)-NO [43,44].
Kinetics of CO binding to HSA-heme-Fe(II) and CO dissoci-
ation from ferrous carbonylated HSA-heme (HSA-heme-Fe(II)-
CO) in the absence of third components displays a multiphasic
reaction pattern which suggests that various heme-protein
coordination forms may coexist in a slow equilibrium among
each other [45]. Here, the effect of the prototypical drug WF on
CO binding to HSA-heme-Fe(II) and CO dissociation from HSA-
heme-Fe(II)-CO and vice versa is reported and a similar behavior
is observed, even though rates and relative percentages of the
multiphasic reaction pattern are affected by WF. In parallel, WF
binding to HSA-heme-Fe(II), in the absence and presence of
saturating CO concentration shows as well multiple exponentials.
The HSA-heme-Fe(II) populations have been characterized by
resonance Raman (RR) spectroscopy, indicating the coexistence of
different species characterized by four-, five- and six-coordination
of the heme-Fe atom. These results highlight the allosteric
modulation of HSA-heme reactivity by heterotropic interaction(s),
and outline the role of drugs in modulating HSA functions. This
work represents a detailed kinetic and thermodynamic study on
the allosteric interaction, employing a drug as an heterotropic
allosteric effector also to outline the important role of HSA as a
drug carrier and the importance of allostery for this function.
Therefore, it represents a very important and widespread
mechanism of action, where allostery works for drug uptake and
delivery, representing the main mechanism regulating the
transport function of HSA.
Materials and Methods
Materials
All reagents were obtained from Sigma-Aldrich (St. Louis, MO,
USA) with the exception of CO that was purchased from Linde
AG (Ho¨llriegelskreuth, Germany) or Rivoira (Milan, Italy), and
13CO that was purchased from FluoroChem (Hadfield, UK). All
chemicals were of the highest purity available and were used
without further purification.
HSA (from Sigma-Aldrich) was FA-free according to the
charcoal delipidation protocol [46-48] and its concentration was
determined by the Bradford assay [49]. Ferric HSA-heme (HSA-
heme-Fe(III)) was prepared by adding the appropriate volume of
the heme-Fe(III) stock solution (i.e., 1.261022 M heme-Fe(III) in
1.061021 M NaOH) to the 1.061023 M HSA stock solution (in
1.061021 M phosphate buffer, pH 7.0) in order to obtain a final
HSA-heme-Fe(III) concentration of about 1.061025 M. Heme-
Fe(III) binding to HSA was monitored spectrophotometrically
using an optical cell with 1.0-cm path length on a Jasco V-53
spectrophotometer (Varian Inc., Palo Alto, USA) in the UV-Vis
region (300–800 nm). The HSA:heme-Fe(III) ratio was about 10:6
and the excess of HSA ensured that the heme-Fe(III) was bound
only to the FA1 site and no free heme-Fe(III) was present in
solution [28]. The heme-Fe(III) concentration was determined
spectrophotometrically at 535 nm after converting hemin to the
heme-Fe(III)-bis-imidazolate derivative in sodium dodecylsulfate
micelles (e535 = 14.5 cm
21 mM21) [50,51]. HSA-heme-Fe(II) was
obtained by adding sodium dithionite (final concentration about
5 mg/ml) to the HSA-heme-Fe(III) solution [52].
The CO stock solution was prepared by keeping anaerobically
in a closed vessel distilled water under CO at P = 760.0 mm Hg
(T = 20uC). The solubility of CO in water is 1.0361023 M, at P
= 760.0 mm Hg and 20uC [52].
The WF stock solution ( = 5.061022 M) was prepared by
dissolving the drug in 1.061021 M phosphate buffer, pH 7.0 and
acetone 20%; acetone (final concentration # 4%) does not affect
spectroscopic properties of the solutions and HSA-heme-Fe(II)
reactivity.
HSA-heme-Fe(II)-CO and warfarin-bound ferrous HSA-heme
(WF-HSA-heme-Fe(II)) solutions were prepared by equilibrating
for 1 hr a HSA-heme-Fe(III) solution (about 1.061025 M), in the
presence of 5 mg/ml of sodium dithionite, with either
1.061024 M CO or 1.061022 M WF. The unusually-long
equilibration time was necessary for the completion of the
reactions, which are characterized by very slow phases (see
Results).
For the RR experiments, HSA-heme-Fe(II)-CO, in the absence
and presence of WF, was prepared by degassing the HSA-heme-
Fe(III) solution by flushing first with nitrogen and then with CO or
13CO and reducing the heme by addition of a 5% volume freshly
prepared sodium dithionite (20 mg/mL) solution; the final heme-
Fe(III):WF molar ratio was 1:1000.
All the experiments have been carried out at pH 7.0
(1.061023 M phosphate buffer and 1.061021 M phosphate
buffer) and 25uC.
Methods
Thermodynamics of WF binding to HSA-heme-Fe(II)
The value of the association equilibrium constant for WF
binding to HSA-heme-Fe(II) (i.e., KWF) was determined spectro-
photometrically (between 380 and 480 nm) by stepwise addition of
the WF stock solution to the HSA-heme-Fe(II) or HSA-heme-
Fe(II)-CO samples and measuring the variations of optical density
as a function of the WF concentration (i.e., [WF]), employing a
double-beam Cary 5 spectrophotometer (Varian, Palo Alto, Ca,
USA). Data were analyzed in the framework of the minimum
reaction mechanism depicted in Figure 2 according to eq. (1),
DOD~DODTot:
KWF : WF½ 
1zKWF : WF½  ð1Þ
Figure 2. Scheme for the WF equilibrium binding to HSA-heme-
Fe(II).
doi:10.1371/journal.pone.0058842.g002
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where DOD is the measured optical density change at 414 nm with
respect to the sample without WF, DODTot is the total optical
density change observed when the sample is saturated with WF
[45].
Kinetics of WF and CO binding to HSA-heme-Fe(II)
Kinetic progress curves for CO binding to HSA-heme-Fe(II), in
the presence of WF, and for WF binding to HSA-heme-Fe(II), in
the absence and presence of CO, have been obtained employing a
SX.18MV stopped-flow apparatus provided with the diode array
accessory for transient spectra collection (Applied Photophysics,
Salisbury, UK). Absorbance spectra have been collected between
380 and 700 nm with a 1.5 ms time resolution.
CO and/or WF association kinetics have been undertaken by
mixing: (i) WF-HSA-heme-Fe(II) with CO (final concentration
ranging between 2.061025 M and 4.061024 M) solution, (ii)
HSA-heme-Fe(II) with WF (final concentration ranging between
561025 M and 1.061022 M) solution, and (iii) HSA-heme-Fe(II)-
CO with WF (final concentration ranging between 561025 M and
1.061022 M) solution. Kinetics of HSA-heme-Fe(II) carbonyla-
tion in the absence of WF has been previously reported [45].
Values of the first-order rate constant for CO dissociation from
HSA-heme-Fe(II)-CO, in the presence of 1.061022 M WF (i.e.,
koffWFCO) were obtained by rapid mixing the protein solution(s) with
the sodium nitrite (final concentration 5.061023 M) solution in
the presence of sodium dithionite (5.0 mg/mL final concentra-
tion). The reaction of sodium dithionite with sodium nitrite
induces a very rapid production of NO; CO replacement by NO is
rate-limited by CO dissociation [45,52]. Kinetics of HSA-heme-
Fe(II)-CO decarbonylation in the absence of WF (i.e., koffCO) has
been previously reported [45].
All kinetic progress curves have been analyzed according to the
following equation:
ODobs~OD0+
Xi~n
i~1
DODi: exp ({
ik:t) ð2Þ
where ODobs is the observed optical density at 414 nm at a given
time interval, OD0 is the optical density at t = 0, n is the number of
exponentials, DODi is the optical density change associated to the
exponential i, ik is the rate constant of the exponential i (referring
to either the ligand binding ikobs or the ligand dissociation
ikoff) and t
is the time [45].
Three types of rate constants for the association of either CO
and/or WF to HSA-heme-Fe(II) have been observed. Namely: (i)
rate constants which are linearly dependent on the ligand (i.e., CO
or WF) concentration, displaying a bimolecular behaviour, (ii) rate
constants, whose ligand concentration dependence is not linear,
showing a rate-limiting step behaviour, and (iii) rate constants
which are independent on the ligand concentration.
Rate constants displaying a bimolecular behaviour have been
analyzed according to the following equation:
kobs~kon| L½ zkoff ð3Þ
where kobs is the observed rate constant, as obtained from the
analysis of the kinetic progress curve according to the Eq. (2), kon is
the second-order association rate constant for the ligand L (i.e.,
either CO or WF), koff is the first-order ligand dissociation rate
constant, and [L] is the ligand concentration (either CO or WF)
[45].
Rate constants displaying a rate-limiting behaviour have been
described by the minimum reaction reported in Figure 3 [53],
where L is an endogenous ligand (likely a protein residue
coordinating the heme), which must dissociate before an
exogenous ligand (i.e., CO or WF) can bind. In the case of CO
as the external ligand, the observed rate constant for the formation
of the final HSA-heme-Fe(II)-(CO) complex (i.e., kobs) has been
described by eq. (4a):
kobs~
k{L:konCO: CO½ 
kzL: L½ zkonCO: CO½ z
koffCO:kzL: L½ 
kzL: L½ zkonCO: CO½  ð4aÞ
Under conditions where the concentration of the endogenous
ligand [L] is constant and k+L’ = k+L6 [L], eq. (4a) reduces to eq.
(4b) [53]:
kobs~
k{L:konCO: CO½ 
k0zLzkonCO: CO½ 
z
koffCO:k
0
zL
k0zLzkonCO: CO½ 
ð4bÞ
Obviously, the equations 4a and 4b apply also in the case of WF
as the exogenous ligand.
Calculation of kinetic and thermodynamic parameters has been
undertaken, employing MatLab version 7.0.(Mathworks, USA).
Spectroscopy of HSA-heme-Fe(II)-CO
Electronic absorption spectra of HSA-heme-Fe(II)-CO, in the
absence and presence of WF, were collected with a double-beam
Cary 5 spectrophotometer (Varian, Palo Alto, CA) using a 5-mm
NMR tube or a 1-mm cuvette, and a 600 nm/min scan rate. RR
spectra were obtained using a 5-mm NMR tube and by excitation
with the 413.1 nm line of a Kr+ laser (Coherent, Innova 300 C,
Santa Clara, CA) and the 441.6 nm line of a HeCd laser (Kimmon
IK4121RG, Tokyo Japan). Backscattered light from a slowly
rotating NMR tube was collected and focused into a triple
spectrometer as previously reported [23]. All RR measurements
were repeated several times under the same conditions to ensure
reproducibility. To improve the signal/noise ratio, a number of
spectra were accumulated and summed only if no spectral
differences were noted. The RR spectra were calibrated with
indene, CCl4, dimethyl sulfoxide, acetone, and acetonitrile as
standards to an accuracy of 1 cm-1 for intense isolated bands.
Results
Thermodynamics of WF binding to HSA-heme-Fe(II)
HSA-heme-Fe(II) binds reversibly WF inducing the , 20%
decrease of the extinction coefficient of HSA-heme-Fe(II) at
414 nm and the shift of the peak wavelength from 414 nm to
Figure 3. Scheme for the CO (and/or WF) binding to the endogenously hexa-coordinated HSA-heme-Fe(II)-L species.
doi:10.1371/journal.pone.0058842.g003
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411 nm (Fig. 4A), at pH 7.0 and 25uC. WF-dependent spectral
changes are essentially completed at 1.061022 M WF (Fig. 4B),
indicating that this concentration saturates the WF binding site of
HSA-heme-Fe(II). However, it must be underlined that the
spectral change(s) following the addition of WF require(s) about
1 hr to reach the equilibrium condition, indicating the occurrence
of a slow equilibration process (see above). Therefore, each
experimental point reported in Fig. 4B refers to the optical density
change(s) attained 1 hr after the addition of WF to HSA-heme-
Fe(II).
WF binding to HSA-heme-Fe(II) follows a simple equilibrium,
the Hill coefficient n being 1.0160.02 (data not shown); therefore,
data reported in Fig. 4B were analyzed in the framework of the
minimum reaction mechanism depicted in Fig. 2. From the
analysis of data according to eq. (1) the value of KWF =
2.2(60.4)6103 M21 was determined. Since we waited species re-
equilibration after WF binding, we observed the overall process of
WF binding to all three HSA-heme-Fe(II) populations [45];
therefore, the resulting equilibrium constant reflects the affinity of
all three HSA-heme-Fe(II) species weighted by their relative
percentage, and it guarantees that at 161022 M WF concentra-
tion all HSA-heme-Fe(II) species are saturated with WF.
Kinetics of WF binding to HSA-heme-Fe(II) and to HSA-
heme-Fe(II)-CO
Figures 5A and 5B show kinetics of WF binding to HSA-heme-
Fe(II) and HSA-heme-Fe(II)-CO, which have been analyzed
according to eq. (2). However, it is worth recalling that WF does
not bind to the heme-Fe(II) atom; therefore, the observed
absorption changes reflect structural changes of the heme-Fe(II)
group upon interaction of WF with Sudlow’s site I (i.e., the FA7
site, and possibly the FA2 cleft) [3,54,55].
Kinetics of WF binding to HSA-heme-Fe(II) is characterized by
three exponentials (Fig. 5A) (as for CO binding, see Fig. S1A) [45],
whose percentage closely mirrors what already reported for CO
binding (therefore n = 3 in eq. (2)). This behaviour indeed was
expected, since the observed population distribution should be
identical with that observed for CO association in the absence of
WF [45]. On the other hand, kinetics of WF binding to HSA-
heme-Fe(II)-CO displays only two exponentials (Fig. 5B) (as for
CO dissociation from HSA-heme-Fe(II)-CO, see Fig. S1C) [45]
whose percentage closely mirrors what observed for CO dissoci-
ation from HSA-heme-Fe(II)-CO in the absence of WF (therefore
n = 2 in eq. (2)). Altogether, the information on the number of
reacting species and on their relative percentage reinforces the
hypothesis that they indeed reflect the apparent equilibrium
constants between the different conformations of HSA-heme-Fe(II)
and HSA-heme-Fe(II)-CO.
WF binding to HSA-heme-Fe(II) and HSA-heme-Fe(II)-CO
shows rate constants much slower than those for CO binding (Figs
5C and 5D and Table 1). The dependence of the rate constants
over the explored WF concentration range allowed to determine
the WF association and dissociation rate constants for the HSA-
heme-Fe(II) and HSA-heme-Fe(II)-CO (see Figs. 5C and 5D).
In particular, for WF binding to HSA-heme-Fe(II) we observed
a very fast phase, amounting to about 10% of the total absorption
change (see Fig. 5A), which should be referred to the same species
characterized by the rate-limiting step behaviour reported for CO
binding (see Fig. S1B). Therefore, the kinetic constant of WF
binding to this species should be identified as 2kobsWF; from the WF
concentration dependence according to eq. (4), values of 2konWF ( =
(4.560.6)6105 M21 s21) and 2koffWF ( = 23.764.1 s
21) have been
determined. A second slower phase, amounting to about 80% of
the total absorption change (see Fig. 5A), displays as well a
bimolecular behaviour (likely referring to the predominant species
for CO binding, see Fig. S1A) and should be identified as 1kobsWF.
The dependence on WF concentration of the rate constant 1kobsWF
according to eq. (3) allowed to determine the 1konWF value ( =
(4.460.6)6102 M21 s21). On the other hand, the third HSA-
heme-Fe(II) species, amounting to about 10% of the total
absorption change, shows a rate-limiting step in the reaction with
WF (see Fig. 5C and Table 1), suggesting that WF binding to FA7
(and/or FA2) [3] is somehow limited by the displacement of some
residue(s).
In the case of WF binding to HSA-heme-Fe(II)-CO, both species
display a bimolecular behavior, thus the dependence of rate
constants on WF concentration has been analysed according to eq.
(3) (see Fig. 5D). From the relative percentage of the two phases, we
can attribute the faster predominant rate constant, amounting to
about 70% of the total absorption change (see Fig. 5B), to the species
corresponding to 1koffCO (see Fig. S1C). Therefore, we can identify
this process with 1kobsCOWF; from the dependence of
1kobsCOWF on the
WF concentration, values of 1konCOWF ( = (1.260.3)610
3 M21 s21)
and 1koffCOWF ( = 0.8960.12 s
21) were calculated according to eq.
Figure 4. Thermodynamics of WF binding to HSA-heme-Fe(II).
(A) Absorption spectral changes accompanying 1.061022 M WF
binding to HSA-heme-Fe(II), at pH 7.0 and 25uC. The equilibration time
was 1 hr. The arrow indicates the direction of the absorption change. (B)
Optical density changes at 414 nm for WF binding to HSA-heme-Fe(II),
at pH 7.0 and 25uC. The continuous line was calculated by the non-
linear least-squares fitting of data according to eq. (1) with KWF =
2.2(60.4)6103 M21. For details, see text.
doi:10.1371/journal.pone.0058842.g004
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(3). The minority population, corresponding to about 30% of the
total absorption change (see Fig. 5B), is instead characterized by
2konCOWF = (1.260.3)610
2 M21 s21 and 2koffCOWF = 0.1460.03
s21.
Kinetics of CO binding to HSA-heme-Fe(II) and WF-HSA-
heme-Fe(II)
Kinetics of CO binding to HSA-heme-Fe(II) displays at pH 7.0
a multiphasic reaction pattern, which can be accounted for by (at
least) three exponentials (Fig. S1A); indeed, kinetics has been
analyzed according to eq. (3) with n = 3 [45] (see Material S1).
Kinetics of CO binding to WF-HSA-heme-Fe(II) displays a
multiphasic reaction pattern, which can be accounted for by (at
least) three exponentials (Fig. 6A) (therefore n = 3 in eq. (2)). In
contrast to CO binding to HSA-heme-Fe(II) [45], drastically
different features occur in the carbonylation of WF-HSA-heme-
Fe(II) (see Fig. S1A), over the whole CO concentration range
explored. Indeed, in the absence of WF most of the HSA-heme-
Fe(II) molecules (about 80%) are in the fast-reacting state (Fig.
S1A) [45], whereas a marked reduction of the fast-reacting state
occurs in the presence of 1.061022 M WF (amounting to about
27%) (Fig. 6A). This change is accompanied by the increase of the
percentage of the other two slow-reacting species, which become
about 19% and 54%, respectively.
The WF-dependent variation of the percentage of the three
HSA-heme-Fe(II) species (see Fig. 6A) indeed reflects the effect of
the binding drug on the distribution of the three populations.
Moreover, the slow spectral changes occurring upon WF addition
to HSA-heme-Fe(II) (see above) are likely related to the slow re-
distribution of the WF-HSA-heme-Fe(II) species.
The effect of CO concentration on values of the three pseudo-
first-order rate constants for WF-HSA-heme-Fe(II) carbonylation
in the presence of 1.061022 M WF (i.e., 1kobsWFCO,
2kobsWFCO, and
3kobsWFCO) (Fig. 6B) shows that, like in the absence of WF, the WF-
HSA-heme-Fe(II) species undergoing the fastest carbonylation
process (characterized by 1kobsWFCO and corresponding to about
27% of the total absorption change, see Fig. 6A) follows a
bimolecular behaviour. The analysis of data shown in Fig. 6B
according to eq. (3) allowed to determine values of 1konWFCO ( =
(5.960.7)6105 M21 s21) and 1koffWFCO ( = (1.260.3)610
21 s21)
(see Table 1).
Figure 5. Kinetics of WF binding to HSA-heme-Fe(II) and HSA-heme-Fe(II)-CO. (A) Kinetic progress curve at 414 nm for WF ( = 2.561023 M)
binding to HSA-heme-Fe(II). Continuous line is the non-linear-least-squares fitting of data according to eq. (2), employing three exponentials (i.e., i =
3). (B) Kinetic progress curve at 414 nm for WF ( = 4.061025 M) binding to HSA-heme-Fe(II)-CO. Continuous line is the non-linear-least-squares fitting
of data according to eq. (2), employing two exponentials (i.e., i = 2). (C) WF concentration dependence of observed rate constants for WF binding to
6cLS(1) (o), 5cHS(1) (x), and 4cIS (o). Continuous lines are the non-linear least-squares fitting of data according to eqs (3) (o,x) and (4b) (*). Kinetic
parameters obtained from the analysis of data are reported in Table 1. (D) WF concentration dependence of the observed rate constants for WF
binding to 6cLS(2) (o) and 6cLS(3) (x). Continuous lines are the non-linear least-squares fitting of data according to eq. (3). Kinetic parameters
obtained from the analysis of data are reported in Table 1.
doi:10.1371/journal.pone.0058842.g005
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In contrast, the pseudo-first-order rate constant for the slowest
process during the carbonylation of WF-HSA-heme-Fe(II) (char-
acterized by 3kobsWFCO = 0.04160.007 s
21) is independent of the
CO concentration, as in the absence of WF (Figs. S1B and 6B, and
Table 1).In the case of the intermediate reactive WF-HSA-heme-
Fe(II) species (characterized by 2kobsWFCO), both in the absence and
presence of 1.061022 M WF, values of the pseudo-first-order rate
constant for WF-HSA-heme-Fe(II) carbonylation do not increase
linearly with the CO concentration, but tend to level off as the CO
concentration increases (Fig. 6B). This behaviour is similar to what
observed in the absence of WF (see Fig. S1B) [45], suggesting that
also in the presence of 1.061022 M WF, one of the species
displays a rate-limiting step, with a behaviour which can be
described in Figure 3 and analyzed according to eq. (4a) [53]. The
levelling off of the CO dependence of 2kobsWFCO (as observed in Fig.
6B) allows to define accurately the value of k-L, but the distinct
information on the relative values of k+L’ and
2konWFCO cannot be
obtained unless 2koffWFCO is calculated independently.
CO dissociation kinetics from WF-HSA-heme-Fe(II)-CO is
characterized by a biphasic kinetic pattern (Fig. 6C), suggesting
that (like in the absence of WF, see Fig. S1C) [45] only two
populations of WF-HSA-heme-Fe(II)-CO are sufficient to account
for the observed behaviour.
As reported for CO dissociation kinetics in the absence of WF
[45], values of the CO dissociation rate constants from the two
WF-bound HSA-heme-Fe(II)-CO conformations display a 10-fold
difference (i.e., 1koffWFCO = 0.1260.03 s
21, and 2koffWFCO =
0.01660.003 s21), in the presence of 1.061022 M WF. Therefore,
binding of WF to HSA-heme-Fe(II)-CO species scarcely affects the
CO dissociation process, since it brings about only a minor 2-fold
variation for the CO dissociation process for either one of the two
liganded conformations; this rules out a linkage between WF
binding to FA7 (and/or FA2) [3] and the CO dissociation energy
barrier. On the other hand, the two (WF-)HSA-heme-Fe(II)-CO
conformations display a quite large difference of the energy barrier
for the CO detachment, the 10-fold difference of rate constant
amounting to an activation free energy change of about 4 kJ/mol.
Spectroscopic characterization
WF-HSA-heme-Fe(II)-CO gives rise to UV-Vis spectra charac-
terized by bands at 419, 539, and 568 nm (Figure 7, top), similar
to the spectra of HSA-heme-Fe(II)-CO at pH 10 [45] and of the
ibuprofen-HSA-heme-Fe(II)-CO complex at neutral pH [23].
However, the UV-Vis spectrum of WF-HSA-heme-Fe(II)-CO is
different from that of HSA-heme-Fe(II)-CO at pH 7.0. In the
corresponding RR spectra (Figure 7, bottom) two [n(Fe-CO)]
stretching modes at 501 and 524 cm21 are observed which shift to
494 and 520 cm21, respectively in 13CO (data not shown). The
corresponding [n(CO)] stretching modes give rise to a broad band
centred at 1960 cm21 (1910 cm21 in 13CO). As a matter of fact,
CO is an excellent vibrational probe to investigate the heme cavity
because Fe-CO back-bonding (from the Fe dp electrons to the
empty CO p* orbitals) is modulated by polar interactions with
protein residues and by variations in the donor strength of the
trans axial ligand. The electrostatic field generated by the polar
distal pocket alters the electron distribution in the Fe-CO unit
changing the bond order of the C-O bond, which can be
monitored by the CO and Fe-C stretching frequencies. The n(Fe-
C) and n(CO) stretching frequencies are inversely correlated and,
from the n(Fe-C) / n(CO) position along the correlation line,
information on the type and the strength of distal polar
interactions are obtained. Moreover, changes in the trans ligand
donor strength shift the correlation line to higher or lower position.
Figure 8 shows the plot of the n(Fe-CO) and n(CO) frequencies
observed in the HSA-heme-Fe(II)-CO complexes under various
experimental conditions. The lines were obtained according to
literature (see eq. 1 reported in ref. [56]). The slope represents the
back-bonding sensitivity of n(Fe-C). The n(Fe-CO) stretching
mode at 524 cm21 and the n(CO) stretch at 1960 cm21 are
located above the His line of the n(Fe–CO)/ n (CO) back-bonding
correlation, since the proximal ligand is either weak [57] or absent
[58]. The stretching mode at 501 cm21 and the n(CO) stretch at
1960cm21 fall on the His n(Fe–CO)/n (CO) back-bonding
correlation line, close to values of HSA-heme-Fe(II)-CO at
alkaline pH and at neutral pH in the presence of 2-methylimi-
dazole or ibuprofen, in which the trans axial ligand is an imidazole
or His [23,45]. These data confirm that in the presence of WF at
neutral pH a major conformational change occurs in the heme
pocket of HSA-heme-Fe(II)-CO, allowing the His146 residue to
coordinate the heme-Fe(II) atom via its nitrogen atom. The
formation of the Fe-N bond has been confirmed by the presence of
the n(Fe-Im) stretching mode upon photolysis of CO in the laser
beam (data not shown). In fact, in the low frequency region of RR
spectra obtained with 441.6 nm excitation of the WF-HSA-heme-
Fe(II)-CO complex at high laser power (35mW), CO is partially
photolyzed giving rise to WF-HSA-heme-Fe(II) which is charac-
terized by a strong band n(Fe-Im) mode at 218 cm21.
Discussion
HSA could be considered as a paradigm for monomeric
allosteric proteins, since the conformational adaptability of HSA
involves more than the immediate vicinity of the binding site(s)
[1,3,11,17,20,23,28,30,31,33,35,40,43,44,54,55,59-65]. In this
work, we have characterized quantitatively the reciprocal allosteric
modulation between the WF and CO binding to HSA-heme-
Fe(II). The choice of these two ligands (i.e., CO and WF) is related
to (i) the relevant physiological role of HSA in heme scavenging
under physiological and pathological condition [3], (ii) the peculiar
role of CO as a neurotransmitter, being involved for example in
the circadian cycle [66,67], and (iii) the widespread utilization of
warfarin as an anticoagulant drug [68].
Table 1. Kinetic parameters for CO and WF binding to
different species of HSA-heme-Fe(II).
kon (M
21 s21) k-L (s
21) kon/k+L koff
CO binding
1kCO (4cIS +
5cHS(1))
4.0(60.5)6106 – – 2.9(60.4)61022
2kCO (6cLS(1)) – 2763.9 6.1(60.8)610
5 2.6(60.4)61021
1kWFCO (WF-
5cHS(1))
5.9(60.7)6105 – – 1.2(60.3)61021
2kWFCO (WF-
6cLS(1))
– 0.8760.11 4.0(60.5)6104 1.6(60.3)61022
WF binding
1kWF (4cIS +
5cHS(1))
4.4(60.6)6102 – – 2.0(60.4)61021
2kWF (6cLS(1)) 4.7(60.7)610
5 – – 2.4(60.4)6101
3kWF 0.04960.006 3.5(60.5)610
3 8.9(61.3)61024
1kCOWF (6cLS(2)) 1.2(60.3)610
3 – – 8.9(61.2)61021
2kCOWF (6cLS(3)) 1.2(60.3)610
2 – – 1.4(60.3)61021
doi:10.1371/journal.pone.0058842.t001
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Observations here reported clearly indicate that HSA-heme-
Fe(II) is characterized by multiple conformational states and/or
heme coordination forms, which display different CO and WF
binding features, underlying a complex functional allosteric
modulation.
The occurrence of three exponentials for the quantitative
description of the CO association kinetic progress curves and of
two exponentials for the CO dissociation time courses has been
recently interpreted [45] as referable to a complex network of
ligand- and proton-linked interactions between the heme and the
neighbouring residues of the FA1 site (i.e., where the heme binds).
In unliganded HSA-heme-Fe(II), three species occur, namely (i) a
four-coordinated form (i.e., 4cIS), (ii) a five-coordinated form with
Tyr161 as axial ligand (i.e., 5cHS(1)) and (iii) a six-coordinated
form with Tyr161 and His146 as axial ligands (i.e., 6cLS(1)) [23].
In addition, three putative CO-bound species (originating from
CO binding to the three unliganded species) occur, namely (i) a
five-coordinated form upon CO binding to 4cIS (i.e., 5cHS(2)), (ii) a
six-coordinated form upon CO binding to 5cHS(1) (i.e., 6cLS(2))
and (iii) a six-coordinated form with His146 as a sixth axial ligand
(i.e., 6cLS(3)), which likely originates from CO binding to the form
6cLS(1) on displacement of Tyr161, ending up with a CO-bound
form where the proximal ligand is His146. This behaviour, which
is also supported by resonance Raman spectra (see Figs. 7, 8, S1A
and S1B), can be accounted only assuming that [45]: (i) in
unliganded HSA-heme-Fe(II) at pH 7.0 the predominant species is
5cHS(1), which is in fast equilibrium with the species 4cIS but in
slow equilibrium with the 6cLS(1) species; (ii) at pH 7.0, the CO-
bound 5cHS(2) species is very unstable and first quickly converts
completely to the 6cLS(2) species, which also shifts slowly toward
the 6cLS(3) species, giving rise to the very slow CO-independent
process (see Fig. S1C); and (iii) at pH 7.0, about 70% of the HSA-
heme-Fe(II)-CO molecules is represented by the 6cLS(2) species.
These informations have been now implemented with those of
CO binding to WF-HSA-heme-Fe(II) and of WF binding to both
HSA-heme-Fe(II) and HSA-heme-Fe(II)-CO; the resulting ther-
modynamic schemes for the two stable species 5cHS(1) (and its
CO-bound form 6cLS(2), see Figure 9) and 6cLS(1) (and its CO-
bound form 6cLS(3), see Figure 10) allow several considerations.
On the basis of thermodynamic considerations (Fig. 9), the CO
equilibrium affinity for 5cHS(1) (KCO (5cHS(1)) = 8.0(61.1)610
6
M21) turns out to be slightly higher than for WF-5cHS(1) (KCO (WF-
5cHS(1)) = 4.9(60.7)6106 M21), envisaging a konCO (5cHS(1)) =
2.3(60.4)6105 M21 s21. This value is considerably slower than that
actually observed (konCO = 4.0(60.5)610
6 M21 s21, see Table 1);
however, this discrepancy is due to the fast equilibrium between the
Figure 6. Kinetics of CO binding to WF-HSA-heme-Fe(II). (A) Kinetic progress curve at 414 nm for CO ( = 7.561025 M) binding HSA-heme in
the presence of WF ( = 1.061022 M) equilibrated for 1 hr. Continuous line is the non-linear-least-squares fitting of data according to eq. (2),
employing three exponentials (i.e., i = 3). Dashed line is the non-linear-least-squares fitting of data according to eq. (2), employing two exponentials
(i.e., i = 2). (B) CO concentration dependence of the rate constants for CO binding in the presence of WF ( = 1.061022 M) to WF-5cHS(1) (o) and WF-
6cLS(1) (x); values described by ‘‘*’’ refer to the rate of species reequilibration (see text). Continuous lines are the non-linear least-squares fitting of
data according to eqs (3) (o) and (4b) (x). Kinetic parameters obtained from the analysis are reported in Table 1. (C) Kinetic progress curve at 414 nm
for CO dissociation from HSA-heme-Fe(II)-CO in the presence of WF ( = 1.061022 M). The optical change corresponds to the displacement of CO by a
large excess of NO. Continuous line represents the non-linear least-squares fitting of data according to eq. (2) (where kobsCO is substituted by koffCO),
employing two exponentials (i.e., i = 2).
doi:10.1371/journal.pone.0058842.g006
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4cIS and 5cHS(1) species, such that the resulting association rate
constant
konCO~konCO(4cIS):
4cIS½ 
4cIS½ z 5cHS(1)½ z
konCO(5cHS(1)):
5cHS(1)½ 
4cIS½ z 5cHS(1)½ 
ð5Þ
Therefore, if we substitute in eq. (5) to konCO (5cHS(1)) the value
of 2.36105, as obtained from Fig. 9, and to konCO (4cIS) the value of
3.46107, as reported for a four-coordinate heme inside a protein
[69], the experimentally observed value of konCO is 4.0(60.5)610
6
M21 s21, employing the 1:8 ratio between populations of 4cIS and
5cHS(1) in HSA-heme-Fe(II).
Furthermore, from Figure 9 it comes out that CO binding to
both 5cHS(1) and WF-5cHS(1) shows association rate constants
closely similar to what observed for mammalian myoglobins (Mbs)
[52]. On the other hand, the CO dissociation rate from WF-
6cLS(2) is significantly faster than in mammalian Mbs [52],
possibly reflecting a weaker heme-protein proximal bond [70],
whereas in the absence of WF the CO dissociation rate from
6cLS(2) is closely similar to those reported for mammalian Mbs
[52]. This suggests that WF binding has a significant effect on CO
dissociation, decreasing by about 3.5 kJ/mol the energy barrier for
the CO detachment from the heme-Fe atom.
As shown in Fig. 9, WF binding to 5cHS(1) is somewhat slower
than drug binding to 6cLS(2), even though 5cHS(1) displays a
slightly higher affinity for WF (KWF (5cHS(1)) = 2.2(60.4)610
3
M21) with respect to 6cLS(2) (KWF (6cLS(2)) = 1.35(60.31)610
3
M21). Therefore, equilibrium CO binding has a moderate
allosteric effect for the interaction of WF with 5cHS(1), in spite
of the significant effect on CO dissociation upon WF binding (see
above).
A completely different behaviour has been observed for the
6cLS(1) species (Figure 10), such that the WF binding rate constant
to 6cLS(1) is about 4000-fold faster than for 6cLS(3) ligation, with a
WF binding equilibrium affinity for 6cLS(1) (KWF (6cLS(1)) =
2.0(60.3)6104 M21) which is 30-fold higher than for 6cLS(3) (KWF
(6cLS(3)) = 7.1(60.9)6102 M21), indeed suggesting a strong CO-
linked allosteric effect for the six-coordinated 6cLS(1) species.
However, it must be underlined that the interaction of WF with
6cLS(1) is also much faster (by about 1000-fold) with respect to all
other species, including the five-coordinated 5cHS(1) form (see Fig.
9 and Table 1). Thus, it comes out that six-coordination of the
heme-Fe atom at the FA1 site lowers the free energy kinetic barrier
for WF association by about 17.2 kJ/mol, with a much more
negative binding free energy for 6cLS(1) (DGWF = 224.4 kJ/mol)
than for the 5cHS(1) species (DGWF = 219.0 kJ/mol). The overall
process appears to be shifted in favour of the WF-6cLS(1) species
also because upon WF binding essentially all the 4cIS species
disappears in favour of the WF-6cLS(1) form.
The functional difference, and thus the allosteric modulation
linked to the proximal ligand of the heme-Fe atom, comes out
clear on comparing the species where the proximal axial ligand is
either Tyr161 (Fig. 9) or His146 (Fig. 10). Therefore, in the case of
WF binding to HSA-heme-Fe(II)-CO the CO-bound 6cLS(2)
species appears to react more quickly with WF (showing a
1konCOWF = (1.260.3)610
3 M21 s21 and 1koffCOWF = 0.8960.12
s21) than the CO-bound 6cLS(3) (with a 2konCOWF =
(1.260.3)6102 M21 s21 and 2koffCOWF = 0.1460.03 s
21). This
indicates that the energy barrier for the access of WF to the FA7
(and/or FA2) [3] site(s) is much lower when the heme is
coordinated to Tyr161 than to His146, being referable to a
decrease of the energy barrier of about 5.6 kJ/mol. On the other
hand, the WF binding equilibrium constant displays a moderate
difference between the two species, suggesting that WF binding
displaces only slightly the equilibrium in favour of the WF-6cLS(2)
form.
The effect of the proximal heme-Fe ligand can be observed also
in the case of HSA-heme-Fe(II)-CO dissociation, since the
biphasic kinetic progress curve (see Fig. S1C) can be accounted
for by the occurrence of two CO-bound species, namely 6cLS(2)
and 6cLS(3) (also detected by resonance Raman spectroscopy, see
Fig. 8), whose rate constants differ in the absence of WF by one
order of magnitude (i.e., koffCO = 0.02960.004 s
21 and 0.2660.04
s21) (see Table 1). Therefore, the energy barrier for the CO
detachment is quite marked between the two forms, the 10-fold
difference of koffCO amounting to an activation free energy lower by
about 4 kJ/mol when His 146 is the proximal heme-Fe ligand.
The situation is completely changed upon addition of WF, since
the rate of CO dissociation from WF-6cLS(2) (1koffWFCO =
0.1260.03 s21, see Table 1) is about ten-fold faster than that for
decarbonylation WF-6cLS(3) (2koffWFCO = 0.01660.003 s
21, see
Table 1), clearly indicating that WF binding stabilizes the bound
CO when His146 is the proximal ligand with an enhancement of
5 kJ/mol for the energy barrier of CO dissociation.
Figure 7. Spectroscopic properties of HSA-heme-Fe(II)-CO.
Electronic absorption (Top) and RR spectra (bottom) of the CO
complexes of HSA-heme-Fe(II)-CO at pH 7 in the presence of warfarin.
RR spectra experimental conditions: 413.1 nm excitation; 1 and
3.3 cm21 spectra resolution for the low and high frequency region,
respectively; 3 mW laser power at the sample; average of 6 spectra (low
frequency region) and 18 spectra (high frequency region) with 300 s
integration time. The intensities are normalized to that of the n4 band
(not shown).
doi:10.1371/journal.pone.0058842.g007
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The interrelationship between WF binding and the strength of
the heme-Fe atom proximal bond emerges also when CO binding
is rate-limited by the displacement of the endogenous ligand (likely
Tyr161). Thus, in the presence of WF the rate of displacement of
the endogenous ligand is about 30-fold slower (see Figure 6B and
Table 1), clearly indicating that the binding of WF to FA7 (and/or
FA2) [3] enhances by about 8.3 kJ/mol the energy barrier for
dissociation of the heme-Fe atom axial ligand Tyr161 (to allow
CO binding and the formation of the WF-6cLS(3) species with
His146 as the axial ligand).
Both CO binding processes to HSA-heme-Fe(II) [45] and to
WF-HSA-heme-Fe(II) are also characterized by a third very slow
phase (characterized by a relaxation rate h = 0.04460.007 s21, in
the absence of WF, and 0.03960.006 s21, in the presence of
1.061022 M WF, and a much larger absorption change amplitude
at 414 nm in the case of WF-HSA-heme-Fe(II) carbonylation, see
Fig. 6A and S1B), which should not reflect a population in the
unliganded form, referring instead to the slow re-equilibration
process between the CO-bound 6cLS(2) and the 6cLS(3) species (or
between the CO-bound WF-6cLS(2) and the WF-6cLS(3) specie).
The much larger apparent slower phase observed during CO
binding to WF-HSA-heme-Fe(II) indeed might be related to the
extensive rearrangement of the CO-bound species between the
WF-6cLS(2) and the WF-6cLS(3) forms, a feature likely related to
Figure 8. Plot of the n(FeC) versus n(CO) frequencies of HSA-heme-Fe(II) under various experimental conditions. Left: Plot of the n(FeC)
versus n(CO) frequencies observed in the CO complexes of heme-HSA under various experimental conditions (right). The lower line indicates the
back-bonding correlation line for six-coordinate CO heme proteins with imidazole as sixth ligand, as given in ref. [49]. The upper line represents five-
coordinate, with no trans ligand, or six-coordinate CO heme proteins with weak trans ligands as Tyr [23].
doi:10.1371/journal.pone.0058842.g008
Figure 9. Thermodynamic and kinetic scheme correlating CO binding to 4cIS, 5cHS(1) and WF-5cHS(1) with WF binding to 5cHS(1)
and 6cLS(2).
doi:10.1371/journal.pone.0058842.g009
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the fact that the 4cIS species is fully destabilized by WF binding,
bringing about a shift in favour of the WF-6cLS(1) species.
As a whole, the allosteric effect exerted by WF binding to its
site(s) seems to be much more pronounced in the unliganded form
of HSA-heme-Fe(II), inducing a strong stabilization of the hexa-
coordinated form mostly by strengthening the Fe-Tyr161 axial
bond, which in turn renders more difficult the detachment of the
axial Tyr161-heme coordination bond upon CO binding. On the
other hand, CO binding abolishes the endogenous hexa-coordi-
nation of the heme-Fe atom, enhancing the kinetic free energy
barrier for WF association; this effect is particularly marked for the
6cLS(2) species, suggesting that the heme-Fe atom coordination by
Tyr161 lowers by about 20 kJ/mol the energy barrier for WF
binding. Therefore, the allosteric mechanism operating in HSA-
heme-Fe(II) between the FA1 and WF binging site(s) appears
modulated mostly by the axial ligands of the heme, with Tyr161
being the most favourable axial ligand for WF interaction.
Supporting Information
Figure S1 (panel A) Kinetic progress curve of CO binding ([CO]
= 4.0610-5 ) to 5.0610-6 M HSA-heme-Fe(II) at pH 7.0 and 25uC
in 1.0610-1 M phosphate buffer. Continuous line: non-linear least-
squares fitting of experimental data according to eq. (2) employing
i = 3. Dashed line: non-linear least-squares fitting of experimental
data according to eq. (2) employing i = 2. (panel B) CO
concentration dependence of the rate constants for CO binding
to HSA-heme-Fe(II). Continuous lines are the non-linear least-
squares fitting of data according to eqs (4) (o) and (5b) (x). Kinetic
parameters obtained from the analysis of data are reported in
Table 1. (panel C) Kinetic progress curve at 414 nm for CO
dissociation from HSA-heme-Fe(II)-CO. The optical change
corresponds to the displacement of the bound CO by a large
excess of NO (see Experimental Procedure). Continuous line
represents the non-linear least-squares fitting of data according to
eq. (2) (where kobsCO is substituted by koffCO), employing two
exponentials (i.e., i = 2).
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